Clinical outcome of patients with mild pre-stroke morbidity following endovascular treatment: a HERMES substudy.

[{"label":"BACKGROUND","text":"Analyses of the effect of pre-stroke functional levels on the outcome of endovascular therapy (EVT) have focused on the course of patients with moderate to substantial pre-stroke disability. The effect of complete freedom from pre-existing disability (modified Rankin Scale (mRS) 0) versus predominantly mild pre-existing disability\/symptoms (mRS 1-2) has not been well delineated."},{"label":"METHODS","text":"The HERMES meta-analysis pooled data from seven randomized trials that tested the efficacy of EVT. We tested for a multiplicative interaction effect of pre-stroke mRS on the relationship between treatment and outcomes. Ordinal regression was used to assess the association between EVT and 90-day mRS (primary outcome) in the subgroup of patients with pre-stroke mRS 1-2. Multivariable regression modeling was then used to test the effect of mild pre-stroke disability\/symptoms on the primary and secondary outcomes (delta-mRS, mRS 0-2\/5-6) compared with patients with pre-stroke mRS 0."},{"label":"RESULTS","text":"We included 1764 patients, of whom 199 (11.3%) had pre-stroke mRS 1-2. No interaction effect of pre-stroke mRS on the relationship between treatment and outcome was observed. Patients with pre-stroke mRS 1-2 had worse outcomes than those with pre-stroke mRS 0 (adjusted common OR (acOR) 0.53, 95% CI 0.40 to 0.70). Nonetheless, a significant benefit of EVT was observed within the mRS 1-2 subgroup (cOR 2.08, 95% CI 1.22 to 3.55)."},{"label":"CONCLUSIONS","text":"Patients asymptomatic\/without disability prior to onset have better outcomes following EVT than patients with mild disability\/symptoms. Patients with pre-stroke mRS 1-2, however, more often achieve good outcomes with EVT compared with conservative management. These findings indicate that mild pre-existing disability\/symptoms influence patient prognosis after EVT but do not diminish the EVT treatment effect."},{"copyright":"\u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ."}]